Advaxis Applies for $2.0 Million U.S. Bio-Defense Grant.

Responds To Solicitation from Northeast Biodefense Center to Develop Oral Formulation of its Proprietary Live Listeria Technology

TARGET: Oral Vaccine Immunizing Large Population In Case Of Pandemic 

NORTH BRUNSWICK, N.J. -- Advaxis, Inc. (OTCBB: ADXS) has applied for a $2 million biodefense grant, in collaboration with a healthcare company (Collaborator), to develop an oral formulation of its live Listeria technology for the prevention of influenza.

This research proposes to use Advaxis' proprietary bioengineered Listeria monocytogenes (Lm) carrier system with a Collaborator's proprietary influenza multi-antigen technology to generate a broad-spectrum oral vaccine against influenza.

This work follows from earlier work performed by Advaxis Scientific Founder Dr. Yvonne Paterson on vaccines directed against influenza antigens. Advaxis will use its latest strain of highly attenuated and antibiotic independent Lm, which was specifically designed for safe use in humans, to develop an oral formulation which will facilitate its use in large populations.

Advaxis CEO Thomas A. Moore said, "Although Advaxis had worked primarily in the development of cancer vaccines, our technology has potentially considerable use in infectious disease applications. Working in the biodefense arena opens up new opportunities for the Company's technology and it's commercialization."

About the Northeast Biodefense Center

The Northeast Biodefense Center (NBC) is a NIAID Region II Center of Excellence for Biodefense and Emerging Infectious Disease Research. The NBC pursues multidisciplinary and interdisciplinary research, fosters training and career development programs, and establishes an array of core facilities to support these research and training activities.

About Advaxis, Inc.

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.

For further information on the Company, please visit: www.advaxis.com.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.